Key result
Intrapericardial bevacizumab yields complete response for malignant pericardial effusion in advanced lung cancer.
Why the study?
Malignant pericardial effusion is a common complication of advanced malignant tumors with limited effective treatments and serious adverse events from standard chemotherapy.
Does intrapericardial bevacizumab improve malignant pericardial effusion in a patient with advanced lung cancer?
Case Report (n=1)
Does intrapericardial bevacizumab improve malignant pericardial effusion in a patient with advanced lung cancer?
Intrapericardial bevacizumab may be an effective treatment option for malignant pericardial effusion in patients with advanced cancer.
Supports pericardial bevacizumab evaluation in MPCE; leaves open its role pending prospective trials.
Malignant pericardial effusion (MPCE) is a common complication of advanced malignant tumors, and interferes severely with patient prognosis and quality of life. The standard treatment for this complication is intracavitary perfusion of chemotherapeutic drugs, which is limited by unsatisfactory therapeutic effects and serious adverse events. We report a patient with MPCE who was treated with bevacizumab by pericardial perfusion, resulting in a complete response. This case supports the use of intrapericardial bevacizumab as a potential treatment for MPCE.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2015) conducted a case report in Malignant pericardial effusion in advanced lung cancer (n=1). Intrapericardial bevacizumab was evaluated on Treatment response. Intrapericardial bevacizumab resulted in a complete response in a patient with malignant pericardial effusion secondary to advanced lung cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: